Tradestie Institutional Equity Comparison Engine

VOR vs WVE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

VOR Overall Edge

VOR Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vor Biopharma Inc. Common Stock (VOR) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VOR trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus WVE at N/M Forward P/E and -320.9% operating margin (+73.0% YoY). In options structure, VOR sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against WVE sits in BREAKDOWN (48th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner VOR
VOR N/M vs WVE N/M Fwd P/E
Growth & Margin Winner VOR
Op Margin 0.0% vs -320.9% ยท YoY +0.0% vs +73.0%
Momentum & Technical Winner VOR
1Y +94.6% vs -57.0% ยท 52W Pos 64% vs 0%
Options & Structure Winner VOR
CONSOLIDATION (6th %ile IV) vs BREAKDOWN (48th %ile IV)
VOR NASDAQ
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$18.97
-2.32% 1D
Market Cap $1.2B
1M Return +5.21%
1Y Return +94.56%
Forward P/E N/M
Unified AI Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
WVE NASDAQ
Wave Life Sciences Ltd. Ordinary Shares
Pharmaceutical Preparations
$2.87
-8.31% 1D
Market Cap $617.3M
1M Return -8.31%
1Y Return -56.97%
Forward P/E N/M
Unified AI Score
41.5 / 100 SELL
Tech 21.0 Fund 46.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VOR +94.56% WVE -56.97% Spread: +151.53 pp (VOR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
VOR TTM Op. Margin: 0.0% WVE TTM Op. Margin: -320.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs WVE. Trailing 12-month operating profitability (VOR 0.0% vs WVE -320.9%) and valuation multiples (VOR N/M vs WVE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VOR (7) vs WVE (2)
Institutional Metric VOR WVE Criterion Row Winner
Market Capitalization Scale $1.2B $617.3M Larger Scale VOR
Trailing P/E Ratio Valuation 0.1x N/M Lower Multiple VOR
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +73.0% Higher Growth WVE
Operating Margin (TTM) Profitability 0.0% -320.9% Higher Margin VOR
Net Profit Margin Profitability 0.0% -296.9% Higher Margin VOR
Return on Equity (ROE) Capital Efficiency -125.4% -78.8% Higher ROE WVE
52-Week Range Position Momentum 64% ($6โ€“$26) 0% ($3โ€“$21) Stronger Trend VOR
Beta / 30D Volatility Risk Regime 1.90ฮฒ ยท 61% Vol 1.94ฮฒ ยท 76% Vol Lower Realized Risk VOR
Unified Institutional Score Composite Signal 57.8 / 100 (HOLD) 41.5 / 100 (SELL) Higher Composite VOR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VOR vs WVE Buy Guide
VOR CONSOLIDATION
52d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live VOR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
WVE BREAKDOWN
149d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 48th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live WVE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VOR nor WVE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.